WATSON PHARMACEUTICALS INC (WPI) is a publicly traded company in the Unknown sector. Across all available filings, 40 corporate insiders have executed 489 transactions totaling $45.6M, demonstrating a bearish sentiment with -$45.6M in net insider flow. The most recent transaction on Oct 31, 2012 involved a transaction of 5,817 shares valued at $0.
No significant insider buying has been recorded for WPI in the recent period.
No significant insider selling has been recorded for WPI in the recent period.
Based on recent SEC filings, insider sentiment for WPI is bearish with an Insider Alignment Score of 0/100 and a net flow of -$45.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at WATSON PHARMACEUTICALS INC (WPI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 40 insiders are actively trading WPI stock, having executed 489 transactions in the past 90 days. The most active insider is David A. Buchen (Executive), who has made 34 transactions totaling $7.3M.
Get notified when executives and directors at WPI file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 31, 2012 | A. Buchen David | Executive | Award | 5,817 | $N/A | $0 | |
| Oct 31, 2012 | Eagan Patrick | Executive | Award | 2,909 | $N/A | $0 | |
| Oct 31, 2012 | Todd Joyce R. | Executive | Award | 5,817 | $N/A | $0 | |
| Oct 31, 2012 | M. Mayr Charles | Executive | Award | 2,909 | $N/A | $0 | |
| Oct 31, 2012 | O. Olafsson Sigurdur | Executive | Award | 14,543 | $N/A | $0 | |
| Oct 31, 2012 | A. Stewart Robert | Executive | Award | 14,543 | $N/A | $0 | |
| Oct 31, 2012 | Fred Wilkinson George | Executive | Award | 2,909 | $N/A | $0 | |
| Sep 1, 2012 | O. Olafsson Sigurdur | Executive | Payment | 811 | $81.35 | $66.0K | |
| Aug 30, 2012 | J. Feldman Michel | Executive | Sale | 5,000 | $81.46 | $407.3K | |
| Aug 30, 2012 | J. Feldman Michel | Executive | Sale | 500 | $81.78 | $40.9K | |
| Aug 24, 2012 | A. Buchen David | Executive | Option Exercise | 706 | $29.43 | $20.8K | |
| Aug 24, 2012 | A. Buchen David | Executive | Sale | 24,294 | $81.56 | $2.0M | Large |
| Aug 24, 2012 | A. Buchen David | Executive | Option Exercise | 24,294 | $29.43 | $715.0K | Large |
| Aug 2, 2012 | W. Bodine Chris | Executive | Gift | 2,600 | $N/A | $0 | |
| Aug 1, 2012 | Todd Joyce R. | Executive | Sale | 2,612 | $78.60 | $205.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 119 | $45.6M | 56.1% |
Exercise(M) | 78 | $27.7M | 34.1% |
Payment(F) | 98 | $8.0M | 9.9% |
Award(A) | 190 | $0 | 0.0% |
Gift(G) | 4 | $0 | 0.0% |
Insider selling pressure at WATSON PHARMACEUTICALS INC has increased, with 40 insiders executing 489 transactions across all time. Total sales of $45.6M significantly outpace purchases of $0, resulting in a net outflow of $45.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.